Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial.
Mitsukuni SuenagaMarta SchirripaShu CaoWu ZhangDongyun YangChiara CremoliniSabina MurgioniSara LonardiYan NingSatoshi OkazakiMartin D BergerYuji MiyamotoAfsaneh BarziFotios LoupakisAlfredo FalconeHeinz-Josef LenzPublished in: Cancers (2020)
RPA2 SNPs may serve as predictive and prognostic markers of oxaliplatin responsiveness in a RAS status-dependent manner in mCRC patients receiving FOLFOXIRI + BEV.